Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia

Hematology Journal

Volumn 5, Issue 2, 2004, Pages 123-129

  Reman, Oumedaly ^a   Buzyn, Agnes ^b   Lhéritier, Veronique ^c   Huguet, Francoise ^d   Kuentz, Mathieu ^e   Stamatoullas, Aspasia ^f   Delannoy, Andre ^g   Fegueux, Nathalie ^h   Micléa, Jean Michel ⁱ   Boiron, Jean Michel ^j   Vernant, Jean Paul ^k   Gardin, Claude ^l   Hacini, Maurice ^m   Georges, Michel ^d   Fière, Denis ^c   Thomas, Xavier ^c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CHU PURPAN   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g Hospital de Jolimont   (Belgium)

^h LAPEYRONIE HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l BEAUJON HOSPITAL   (France)

^m CENTRE HOSPITALIER DE CHAMBÉRY   (France)

more..

Author keywords

Acute lymphoblastic leukemia; Bone marrow transplantation; Prognosis; Relapse

Indexed keywords

AMSACRINE; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW RESCUE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; SALVAGE THERAPY; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AMSACRINE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 11144357200     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200353     Document Type: Article

References (27)

1. Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of UK. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on leukaemia in adults. Br J Haematol 1997; 99: 84.
2. Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11: 1990.
3. Hoelzer D, Thiel E, Ludwig WD, Löffler H, Büchner T, Freund M et al. for the German Adult ALL Study Group. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). Leukemia 1993; 7(Suppl 2): S130.
4. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia Group B study 8811. Blood 1995; 85: 2025.
5. Mandelli F, Annino L, Rotoli B, for the GIMEMA Cooperative Group. The GIMEMA ALL 0183 trial, analysis of 10-year follow-up. Br J Haematol 1996; 92: 663.
6. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547.
7. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 1994; 45: 341.
8. Garcia-Maneiro G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 163.
9. Arlin ZA, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S et al. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastique leukemia in adults. Blood 1988; 72: 433.
10. Milpied N, Gisselbrecht C, Harousseau JL, Sebban C, Witz F, Troussard X et al. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone and etoposide (PAME) chemotherapy. Cancer 1990; 66: 627.
11. Peters WG, Willemze R, Colly LP. Intermediate and high dose arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: The Leyden experience and review of the literature. Semin Oncol 1987; 86: 1987.
12. Marit G, Cony-Makhoul P, Duclos F, Puntous M, Broustet A, Reiffers J. Treatment of relapsed or refractory acute leukemia: comparison of two different regimens. Haematol Blood Transfus 1990; 33: 614.
13. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76: 473.
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451.
15. Boucheix C, David B, Sebban C, Racadot E, Bené MC, Bernard A et al. Immunophenotype of adult acute lymphoblastic leukaemia, clinical parameters, and outcome: an analysis of the prospective trial including 562 tested patients (LALA87). French group on therapy for adult acute lymphoblastic leukemia. Blood 1994; 84: 1603.
16. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Intensive therapy in 922 adult patients with acute lymphoblastic leukemia (ALL): Analysis of the French-Belgian-Swiss-Australian LALA-94 trial. Blood 2002; 100: 156a.
17. Preisler HD. Failure of remission induction in acute myelocytic leukemia. Med Ped Oncol 1978; 4: 275.
18. World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, 48, WHO; Geneva: 1979.
19. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology 1993; 7: 23.
20. Herzig RH, Bortin MM, Barrett AJ, Blume KG, Gluckman E, Horowitz MM et al. Bone marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1987; 1: 786.
21. Barrett A, Horowitz M, Gale R, Biggs JC, Camitta BM, Dicke K et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862.
22. Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7: 453.
23. Advisory Committee of IBMTR: Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 221.
24. Davies SM, Ramsay NK, Weisdorf DJ. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 1996; 17: 737.
25. Arcese W, Meloni G, Giona F, Vegna ML, Testi AM, Annino L et al. Idarubicin plus ARA-C followed by allogeneic or autologous bone marrow transplantation in advanced acute lymphoblastic leukemia. Bone Marrow Transplant 1991; 7(Suppl 2): 38.
26. Faderl S, Kantarjian HM, O'Brien S, Cortes J, Thomas DA, Giles F et al. A broad exploratory trial of Campath-1H in the treatment of acute leukemias. Blood 2000; 96: 324a.
27. Thomas D, Cortes J, Giles F, Faderl S, O'Brien S, Garcia-Manero G, et al. Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood 2001; 98 (Suppl 1): 804a.